Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease
Authors:
- Aleksandra BanaszkiewiczABAleksandra Banaszkiewicz
- Brygida TargońskaBTBrygida Targońska
- Kinga Kowalska-DuplagaKKKinga Kowalska-Duplaga
- Katarzyna Karolewska-BochenekKKKatarzyna Karolewska-Bochenek
- Agnieszka SieczkowskaASAgnieszka Sieczkowska
- Agnieszka GawrońskaAGAgnieszka Gawrońska
- Urszula Grzybowska-ChlebowczykUGUrszula Grzybowska-Chlebowczyk
- Elżbieta KrzesiekEKElżbieta Krzesiek
- Izabella Łazowska-PrzeorekIŁIzabella Łazowska-Przeorek
- Maria KotowskaMKMaria Kotowska
- Edyta SienkiewiczESEdyta Sienkiewicz
- Jarosław WalkowiakJWJarosław Walkowiak
- 1 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (7) , 1607-1614
Abstract
There are only a few studies on immune response to pneumococcal vaccines in patients with inflammatory bowel disease (IBD); all of them assessed polysaccharide vaccines only. The aim of the study was to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in IBD pediatric patients compared with healthy controls. This was a multicenter, prospective, and controlled study on children and adolescents aged 5 to 18 years with IBD with no history of pneumococcal immunization. The subjects for the study belonged to one of the following groups: patients with IBD on no immunosuppressive therapy (group A), those on tumor necrosis factor agents or immunomodulators (group B), and healthy controls (group C). The study population received 1 intramuscular injection of PCV13. The primary outcome measure was adequate vaccine response defined as postvaccination titer ≥0.35 μg/mL to all 13 serotypes. Geometric mean titers and geometric mean titer rises were measured for all serotypes. The evidence of local and systemic adverse effects for 5 days after the vaccine was registered. A total of 178 subjects (122 patients and 56 controls) completed the study course. There was no significant difference in the rate of adequate vaccine response between patients with IBD and controls measured 4 to 8 weeks after vaccination (90.4% versus 96.5%, P = 0.5281). Children in group A had higher geometric mean titer rises than children in group B (P = 0.0369). There were no serious adverse events related to PCV13 during the study. PCV13 is both immunogenic and safe in pediatric patients with IBD.Keywords
This publication has 32 references indexed in Scilit:
- Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111Emerging Infectious Diseases, 2013
- Increased Risk of Pneumonia Among Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2013
- The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Association of Serotype of Streptococcus pneumoniae With Risk of Severe and Fatal OutcomeThe Pediatric Infectious Disease Journal, 2009
- Epidemiology of community-acquired pneumonia in children seen in hospitalEpidemiology and Infection, 2006
- Population-Based Incidence of Severe Pneumonia in Children in Kiel, GermanyKlinische Padiatrie, 2005
- Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal PolysaccharidesClinical and Vaccine Immunology, 2003
- Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent AssayClinical and Diagnostic Laboratory Immunology, 2001
- Alternatives to the Median Absolute DeviationJournal of the American Statistical Association, 1993